Skip to main content
Top
Published in: Current Treatment Options in Neurology 1/2010

01-01-2010 | Neurologic Ophthalmology and Otology

Treatment of Thyroid Eye Disease

Authors: Margaret E. Phillips, MD, Mehrak M. Marzban, MD, Sajeev S. Kathuria, MD

Published in: Current Treatment Options in Neurology | Issue 1/2010

Login to get access

Opinion statement

Thyroid eye disease (TED) is an autoimmune disease characterized by varying degrees of proptosis, congestion and inflammation of the extraocular tissues, and eyelid retraction. It is usually seen in the setting of Graves’ disease, but the severity of TED does not necessarily correlate with the level of systemic disease in a given patient. It is very important, nonetheless, to try to achieve a euthyroid state to minimize the chances of exacerbation of TED. Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking, because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations. Once there is significant improvement in the acute inflammation, it is useful to treat patients who have residual inflammation with external beam radiation in order to be able to wean the patient off steroids and avoid their well-known complications.
If there is significant corneal exposure due to lid retraction, and the lid position has been stable for at least 6 months, eyelid surgery can be considered. If exposure is minimal, this may consist of a lateral tarsorrhaphy. For larger amounts of exposure, recession of the levator muscle, Müller’s muscle, or both can be performed. Those patients who have stable diplopia for at least 6 months are candidates for strabismus surgery. Patients who progress to severe proptosis or compressive optic neuropathy may need orbital decompression surgery. Generally, if more than one type of surgical procedure is necessary, orbital decompression is performed first, followed by strabismus surgery; eyelid surgery is performed last.
Literature
1.
go back to reference Bartley GB, Fatourechi V, Kadrmas EF, et al.: Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996, 121:284–290.PubMed Bartley GB, Fatourechi V, Kadrmas EF, et al.: Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996, 121:284–290.PubMed
2.
go back to reference Bartley GB: The epidemiological characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994, 92:477–588.PubMed Bartley GB: The epidemiological characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994, 92:477–588.PubMed
3.
go back to reference Wiersanga WM, Bartalena L: Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002, 12(10):855–860.CrossRef Wiersanga WM, Bartalena L: Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002, 12(10):855–860.CrossRef
4.
go back to reference Manji N, Carr-Smith JD, Boelaert K, et al.: Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 2006, 91:4873–4880.CrossRefPubMed Manji N, Carr-Smith JD, Boelaert K, et al.: Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 2006, 91:4873–4880.CrossRefPubMed
5.
go back to reference Eckstein AK, Johnson KTM, Thanos M, et al.: Current insights into the pathogenesis of Graves’ orbitopathy [review]. Horm Metab Res 2009, 41:456–464.CrossRefPubMed Eckstein AK, Johnson KTM, Thanos M, et al.: Current insights into the pathogenesis of Graves’ orbitopathy [review]. Horm Metab Res 2009, 41:456–464.CrossRefPubMed
6.
go back to reference Lee HB, Rogers IR, Woog JJ: Evaluation and management of Graves’ orbitopathy. Otolaryngol Clin N Am 2006, 39:923–942.CrossRef Lee HB, Rogers IR, Woog JJ: Evaluation and management of Graves’ orbitopathy. Otolaryngol Clin N Am 2006, 39:923–942.CrossRef
7.
go back to reference Aktaran S, Akarsu E, Araz M, et al.: Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract 2007, 61(1):45–51.CrossRefPubMed Aktaran S, Akarsu E, Araz M, et al.: Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract 2007, 61(1):45–51.CrossRefPubMed
8.
go back to reference •Bradley EA, Gower EW, Bradley DJ, et al.: Orbital radiation for Graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008, 115:398–409.This article provides a concise review of the available case studies and randomized controlled trials with respect to orbital radiation in TED. •Bradley EA, Gower EW, Bradley DJ, et al.: Orbital radiation for Graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008, 115:398–409.This article provides a concise review of the available case studies and randomized controlled trials with respect to orbital radiation in TED.
9.
go back to reference Chong KKL, Khanna D, Afifiyan NF, et al.: Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2009 Oct 7 (Epub ahead of print). Chong KKL, Khanna D, Afifiyan NF, et al.: Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2009 Oct 7 (Epub ahead of print).
Metadata
Title
Treatment of Thyroid Eye Disease
Authors
Margaret E. Phillips, MD
Mehrak M. Marzban, MD
Sajeev S. Kathuria, MD
Publication date
01-01-2010
Publisher
Current Science Inc.
Published in
Current Treatment Options in Neurology / Issue 1/2010
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-009-0054-0

Other articles of this Issue 1/2010

Current Treatment Options in Neurology 1/2010 Go to the issue

Neurologic Ophthalmology and Otology

Treatment of Melanoma-Associated Retinopathy

Neurologic Ophthalmology and Otology

Treatment of Carotid Cavernous Fistulas

Neurologic Ophthalmology and Otology

Nonvestibulocochlear Cranial Nerve Schwannomas